April 26, 2021
AireHealth Appoints Kien Nguyen as Chief Executive Officer
ORLANDO, Fla. – (April 26, 2021) -- AireHealth, a respiratory digital health company based in the U.S., announced today that its Board of Directors has appointed Kien Nguyen as Chief Executive Officer and a member of the AireHealth Board of Directors effective immediately. Mr. Nguyen is a proven medical device and technology leader with a distinguished track record of product innovation, market development and commercialization. His career spans nearly three decades leading global teams within medical device and life sciences industries for both start-up and Fortune 500 companies, most recently serving as Chief Commercial Officer at Progenerative Medical. Mr. Nguyen has also received multiple advanced degrees including a Master of Business Administration from Columbia University and a Doctorate in Neuroscience from the University of Colorado.
“Kien is absolutely the right person to lead AireHealth as we enter this next phase of innovation and growth,” said Stacie Ruth, co-founder and Board Director. “Kien’s ability to translate technologies into solutions with high market value and his deep commercialization expertise will accelerate the execution of AireHealth’s mission to improve the lives of millions of people living with chronic lung disease.”
AireHealth recently received 510(k) clearance for a connected nebulizer from the FDA to address the growing challenges in chronic respiratory illness that cost more than $130 billion per year and are the cause of nearly 50 deaths per 100,000 people. The portable, connected AireHealth nebulizer is part of a comprehensive digital health platform designed to track medication adherence, symptoms, and behaviors to enable earlier clinician intervention and reduce unnecessary hospitalization.
“I am honored to have been chosen by AireHealth’s board of directors to lead the company,” said Mr. Nguyen. “AireHealth is truly revolutionizing respiratory care for people living with chronic respiratory illness and their care teams. My primary focus will be to work with the board and a talented , passionate leadership team to execute on the strategy and vision to bring meaningful respiratory care innovation to market faster.”
Learn more about AireHealth and how their digital solution can support chronic care management and remote patient monitoring programs for healthcare providers.
AireHealth is an innovative digital health company empowering and improving healthy living through affordable treatments, symptom tracking and early detection of respiratory conditions. With strong IP and clinically validated products in our pipeline, the company enables more proactive care and early interventions to improve outcomes and reduce costs.
The company provides monitored drug delivery through its FDA cleared Class II portable nebulizer, designed to deliver medicine directly to a patient’s lungs where it is most effective. AireHealth’s digital platform allows for earlier detection of respiratory decline through connected devices, the MyAirHealth diary companion app, and provider portal. The result is that patients not only take a more proactive approach to managing their respiratory care but enables faster clinical intervention and fewer hospitalizations, which helps achieve the goal of improving treatment outcomes and lowering costs. For more information, please visit Aire.Health.
AireHealth and LucidAct Health Partner in Connecting In-Home Chronic Respiratory Patients with their Provider Care Teams
LucidAct Health, the leading care coordination platform for virtual care, is pleased to announce integration of their LucidAct Provider Portal with AireHealth’s digital health solution to support remote management of chronic obstructive pulmonary disease (COPD) and other chronic respiratory conditions.
As of January 2021, the Centers for Medicare & Medicaid Services (CMS) has approved over 56 hospitals for its hospital-care-at-home model, which studies have shown to improve outcomes and lower cost, with the added benefit of patients being able to recover in the comfort of their homes. The CMS has stated that with proper monitoring, more than 60 conditions including congestive heart failure (CHF), COPD, and pneumonia can be treated in home settings.
Annually, delayed diagnosis and treatment, poor adherence, and preventable hospitalization contribute to over $130B of unnecessary costs. Further, respiratory conditions such as Asthma, COPD, respiratory viruses, pneumonia, and cystic fibrosis account for 49.2 deaths per 100,000.
The AireHealth digital health solution includes an FDA-cleared connected portable nebulizer and diary companion app with the following features:
Lightweight and quiet portable design to empower people with COPD and other chronic respiratory conditions to stay connected with care teams and live their life on-the-go
MyAireHealth diary companion app enables care teams to monitor data for treatment adherence and actionable symptoms to proactively identify and triage their high-risk respiratory patients
Bluetooth wireless data transmission to LucidAct, which in turn integrates with the provider’s EMR to support clinical decision-making, helping to reduce unnecessary hospital readmissions